238 related articles for article (PubMed ID: 19258950)
41. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
42. Incidence of para-aortic and pelvic lymph node metastases in epithelial carcinoma of the ovary.
Chen SS; Lee L
Gynecol Oncol; 1983 Aug; 16(1):95-100. PubMed ID: 6884834
[TBL] [Abstract][Full Text] [Related]
43. Surgical staging of ovarian low malignant potential tumors.
Rao GG; Skinner E; Gehrig PA; Duska LR; Coleman RL; Schorge JO
Obstet Gynecol; 2004 Aug; 104(2):261-6. PubMed ID: 15291997
[TBL] [Abstract][Full Text] [Related]
44. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential.
Leake JF; Rader JS; Woodruff JD; Rosenshein NB
Gynecol Oncol; 1991 Aug; 42(2):124-30. PubMed ID: 1894170
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of microinvasion and lymph node involvement in ovarian serous borderline/atypical proliferative serous tumors: a morphologic and immunohistochemical analysis of 37 cases.
Maniar KP; Wang Y; Visvanathan K; Shih IeM; Kurman RJ
Am J Surg Pathol; 2014 Jun; 38(6):743-55. PubMed ID: 24441661
[TBL] [Abstract][Full Text] [Related]
46. The involvement of retroperitoneal lymph nodes in primary serous-papillary peritoneal carcinoma. a systematic review of the literature.
Steinhagen PR; Sehouli J
Anticancer Res; 2011 Apr; 31(4):1387-94. PubMed ID: 21508390
[TBL] [Abstract][Full Text] [Related]
47. Assessing the landscape of ovarian serous borderline tumors.
Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
[TBL] [Abstract][Full Text] [Related]
48. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
[TBL] [Abstract][Full Text] [Related]
49. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
50. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
51. Ovarian serous borderline tumors with lymph node involvement. Clinicopathologic and DNA content study of seven cases and review of the literature.
Tan LK; Flynn SD; Carcangiu ML
Am J Surg Pathol; 1994 Sep; 18(9):904-12. PubMed ID: 8067511
[TBL] [Abstract][Full Text] [Related]
52. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
53. [Endosalpingiosis of the axillary lymph nodes--primary or metastatic tumour?].
Stolnicu S; Mocan S; Coros MF; Rădulescu D; Bara T
Chirurgia (Bucur); 2005; 100(3):297-300. PubMed ID: 16106940
[TBL] [Abstract][Full Text] [Related]
54. Factors associated with the involvement of lymph nodes in low-grade serous ovarian cancer.
Durmuş Y; Meydanlı MM; Akıllı H; Kayıkçıoğlu F; Güngördük K; Akbayır Ö; Taşkın S; Çelik H; Ayhan A
J Surg Oncol; 2022 Feb; 125(2):264-272. PubMed ID: 34610148
[TBL] [Abstract][Full Text] [Related]
55. Lymph node-positive stage IIIC ovarian cancer: a separate entity?
Berek JS
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S18-20. PubMed ID: 19955908
[TBL] [Abstract][Full Text] [Related]
56. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
57. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer.
Burghardt E; Girardi F; Lahousen M; Tamussino K; Stettner H
Gynecol Oncol; 1991 Feb; 40(2):103-6. PubMed ID: 2010101
[TBL] [Abstract][Full Text] [Related]
58. Clinicopathological factors of pelvic lymph nodes involvement in advanced serous ovarian cancer.
Piatek S; Golawski K; Panek G; Bidzinski M; Wielgos M
Ginekol Pol; 2020; 91(2):68-72. PubMed ID: 32141051
[TBL] [Abstract][Full Text] [Related]
59. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.
Morice P; Joulie F; Camatte S; Atallah D; Rouzier R; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Aug; 197(2):198-205. PubMed ID: 12892797
[TBL] [Abstract][Full Text] [Related]
60. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
